SUPN (Supernus Pharma) Pangali EV/EBITDA

Supernus Pharmaceuticals (SUPN) relies on the success of new drugs and patent protection within the CNS field. The company's environmental footprint is minimal due to strict control of office waste. Revenues are based on the sales of high-margin drugs Qelbree and Trokendi XR. This chart from the GURU.Markets platform illustrates the change in the company's EV/EBITDA level, where 10.16 reflects the current value of this multiple.

For the Supernus Pharmaceuticals (SUPN) pharma ecosystem, which focuses on CNS therapy, this ratio serves as a measure of business value relative to its operating efficiency before interest and taxes. By analyzing the historical EV/EBITDA trend of Supernus Pharmaceuticals (SUPN), an investor can determine the fairness of the asset's market valuation amid the expansion of the pediatric segment and risks of patent expiration, allowing for the timely identification of overvalued or undervalued shares.